These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 37395856)

  • 1. Monoclonal Antibodies in Oncology: A Decade of Novel Options.
    Kardile V; Kulkarni A; Nadar B; Saldanha T
    Cell Biochem Biophys; 2023 Sep; 81(3):395-408. PubMed ID: 37395856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune checkpoints and cancer development: Therapeutic implications and future directions.
    Mehdizadeh S; Bayatipoor H; Pashangzadeh S; Jafarpour R; Shojaei Z; Motallebnezhad M
    Pathol Res Pract; 2021 Jul; 223():153485. PubMed ID: 34022684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A systematic review of head-to-head trials of approved monoclonal antibodies used in cancer: an overview of the clinical trials agenda.
    Luo J; Nishikawa G; Prasad V
    J Cancer Res Clin Oncol; 2019 Sep; 145(9):2303-2311. PubMed ID: 31396700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel immune check point inhibiting antibodies in cancer therapy-Opportunities and challenges.
    Diesendruck Y; Benhar I
    Drug Resist Updat; 2017 Jan; 30():39-47. PubMed ID: 28363334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of Resistance to Monoclonal Antibodies (mAbs) in Lymphoid Malignancies.
    Torka P; Barth M; Ferdman R; Hernandez-Ilizaliturri FJ
    Curr Hematol Malig Rep; 2019 Oct; 14(5):426-438. PubMed ID: 31559580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 2, immune checkpoint inhibitor antibodies.
    Desnoyer A; Broutin S; Delahousse J; Maritaz C; Blondel L; Mir O; Chaput N; Paci A
    Eur J Cancer; 2020 Mar; 128():119-128. PubMed ID: 32037060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoclonal Antibodies: A Review.
    Singh S; Kumar NK; Dwiwedi P; Charan J; Kaur R; Sidhu P; Chugh VK
    Curr Clin Pharmacol; 2018; 13(2):85-99. PubMed ID: 28799485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibodies in oncology.
    Pillay V; Gan HK; Scott AM
    N Biotechnol; 2011 Sep; 28(5):518-29. PubMed ID: 21473941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic Monoclonal Antibodies in Clinical Practice against Cancer.
    Kaur N; Goyal A; Sindhu RK
    Anticancer Agents Med Chem; 2020; 20(16):1895-1907. PubMed ID: 32619180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New monoclonal antibodies in renal transplantation.
    Vincenti F
    Minerva Urol Nefrol; 2003 Mar; 55(1):57-66. PubMed ID: 12773967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The importance of immune checkpoints in immune monitoring: A future paradigm shift in the treatment of cancer.
    Alemohammad H; Najafzadeh B; Asadzadeh Z; Baghbanzadeh A; Ghorbaninezhad F; Najafzadeh A; Safarpour H; Bernardini R; Brunetti O; Sonnessa M; Fasano R; Silvestris N; Baradaran B
    Biomed Pharmacother; 2022 Feb; 146():112516. PubMed ID: 34906767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer Immunotherapy: The Dawn of Antibody Cocktails.
    Marrocco I; Romaniello D; Yarden Y
    Methods Mol Biol; 2019; 1904():11-51. PubMed ID: 30539465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding the Monoclonal Antibody Involvement in Targeting the Activation of Tumor Suppressor Genes.
    Mishra RK; Ahmad A; Vyawahare A; Kumar A; Khan R
    Curr Top Med Chem; 2020; 20(20):1810-1823. PubMed ID: 32543361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoclonal antibodies as targeted therapy in hematologic malignancies in older adults.
    Rao AV; Schmader K
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):247-62. PubMed ID: 17996665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The FDA Oncology Center of Excellence and precision medicine.
    Goldberg KB; Blumenthal GM; McKee AE; Pazdur R
    Exp Biol Med (Maywood); 2018 Feb; 243(3):308-312. PubMed ID: 29105511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influencing tumor-associated macrophages in malignant melanoma with monoclonal antibodies.
    Adams R; Osborn G; Mukhia B; Laddach R; Willsmore Z; Chenoweth A; Geh JLC; MacKenzie Ross AD; Healy C; Barber L; Tsoka S; Sanz-Moreno V; Lacy KE; Karagiannis SN
    Oncoimmunology; 2022; 11(1):2127284. PubMed ID: 36211808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibodies to watch in 2010.
    Reichert JM
    MAbs; 2010; 2(1):84-100. PubMed ID: 20065640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy for cancer treatment.
    Donátová K; Nováková E; Šupolíková M
    Klin Onkol; 2022; 35(4):284-289. PubMed ID: 35989085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The diverse landscape of dermatologic toxicities of non-immune checkpoint inhibitor monoclonal antibody-based cancer therapy.
    Seervai RNH; Friske SK; Chu EY; Phillips R; Nelson KC; Huen A; Cho WC; Aung PP; Torres-Cabala CA; Prieto VG; Curry JL
    J Cutan Pathol; 2023 Jan; 50(1):72-95. PubMed ID: 36069496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Massive parallel screening of phage libraries for the generation of repertoires of human immunomodulatory monoclonal antibodies.
    Sasso E; D'Avino C; Passariello M; D'Alise AM; Siciliano D; Esposito ML; Froechlich G; Cortese R; Scarselli E; Zambrano N; Nicosia A; De Lorenzo C
    MAbs; 2018 Oct; 10(7):1060-1072. PubMed ID: 29995563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.